Summary
CTI BioPharma Corp (CTI BioPharma), formerly Cell Therapeutics, Inc., is a biopharmaceutical company, which acquires, develops, and commercializes targeted therapies for a range of blood-related cancers. The company’s lead product, Pixuvri (pixantrone dimaleate) is an aza-anthracenedione that is used for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). Its pipeline portfolio consists of compounds for the treatment of multiply relapsed aggressive B-cell NHL, myelofibrosis for all platelet counts, ovarian cancer, myelodysplastic syndromes, and relapsed acute myeloid leukemia. The company has subsidiaries in Europe and the US. CTI BioPharma is headquartered in Seattle, Washington, the US.
CTI BioPharma Corp (CTIC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
CTI BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Cell Therapeutics Acquires Pacritinib From S*BIO For US$30 Million 10
Venture Financing 11
CTI BioPharma Announces Venture Debt Financing 11
Licensing Agreements 12
CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 12
CTI BioPharma Enters into Licensing Agreement with Servier for Pixuvri 13
Equity Offering 15
CTI BioPharma Raises USD55 Million in Public Offering of Series N-2 Preferred Stock 15
CTI BioPharma Raises USD50 Million in Public Offering of Shares 16
CTI BioPharma Raises USD15.7 Million in Private Placement of Shares 18
CTI BioPharma Raises USD35 Million in Public Offering of Preferred Shares 19
Cell Therapeutics Completes Private Placement Of Preferred Stock For US$15 Million 21
Cell Therapeutics Completes Public Offering Of Preferred Stock For US$60 Million 22
Cell Therapeutics Completes Second Tranche Of Private Placement Of Series 15-2 Convertible Preferred Stock For US$15 Million 24
Cell Therapeutics Completes Private Placement Of Series 14 Preferred Stock For US$20 Million 25
Cell Therapeutics Completes Private Placement Of Series 13 Preferred Stock For US$30 Million 26
Cell Therapeutics Completes Private Placement Of Series 12 Preferred Stock For US$16 Million 28
Cell Therapeutics Completes Private Placement Of US$25 Million 29
Cell Therapeutics Completes Registered Offering Of US$25 Million 30
CTI BioPharma Corp - Key Competitors 33
Key Employees 34
Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36List of Tables
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2015 1
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
CTI BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
CTI BioPharma Corp, Deals By Therapy Area, 2011 to YTD 2017 8
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Cell Therapeutics Acquires Pacritinib From S*BIO For US$30 Million 10
CTI BioPharma Announces Venture Debt Financing 11
CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 12
CTI BioPharma Enters into Licensing Agreement with Servier for Pixuvri 13
CTI BioPharma Raises USD55 Million in Public Offering of Series N-2 Preferred Stock 15
CTI BioPharma Raises USD50 Million in Public Offering of Shares 16
CTI BioPharma Raises USD15.7 Million in Private Placement of Shares 18
CTI BioPharma Raises USD35 Million in Public Offering of Preferred Shares 19
Cell Therapeutics Completes Private Placement Of Preferred Stock For US$15 Million 21
Cell Therapeutics Completes Public Offering Of Preferred Stock For US$60 Million 22
Cell Therapeutics Completes Second Tranche Of Private Placement Of Series 15-2 Convertible Preferred Stock For US$15 Million 24
Cell Therapeutics Completes Private Placement Of Series 14 Preferred Stock For US$20 Million 25
Cell Therapeutics Completes Private Placement Of Series 13 Preferred Stock For US$30 Million 26
Cell Therapeutics Completes Private Placement Of Series 12 Preferred Stock For US$16 Million 28
Cell Therapeutics Completes Private Placement Of US$25 Million 29
Cell Therapeutics Completes Registered Offering Of US$25 Million 30
CTI BioPharma Corp, Key Competitors 33
CTI BioPharma Corp, Key Employees 34
CTI BioPharma Corp, Subsidiaries 35List of Figures
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
